Q-omics provides the consensus-scored RMDN3 profile across patient tissues and cancer cell-line models. RMDN3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RMDN3 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, RMDN3 RNA expression shows 20,446 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, LUAD, and ACC as cancer lineages where RMDN3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RMDN3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RMDN3 survival associations across molecular data types. RMDN3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RMDN3 RNA expression–survival associations across cancer types. High RMDN3 expression shows unfavorable associations in HNSC, ACC, UVM and BLCA, but favorable associations in KIRC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RMDN3 RNA expression.
This table summarizes RMDN3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in LUAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RMDN3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RMDN3 shows lower tumor expression in LUAD, LUSC and THCA and higher tumor expression in HNSC, STAD and ESCA. The LUAD box plot shows higher RMDN3 RNA expression in normal versus tumor tissue (log2 FC = −1.106, t-test p < 0.001).
This table shows molecular features associated with RMDN3 in patient tissues and cancer cell lines. In patient samples, RMDN3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RMDN3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
